ImmunologybioRxivPreprint
Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy
Matthew P. Zimmerman, Amy Y. Huang, Emily K. Cox…·Brian C. Miller
This study shows CD40 agonist therapy reduces tumor growth in antigen presentation-deficient tumors by reprogramming monocytes and requiring IFN-gamma and CD8+ T cells for efficacy.